These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 35459391)
61. Calcium and phosphorus in diet therapy of uremia. Schoolwerth AC; Engle JE J Am Diet Assoc; 1975 May; 66(5):460-4. PubMed ID: 1123506 [TBL] [Abstract][Full Text] [Related]
62. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308 [TBL] [Abstract][Full Text] [Related]
63. Chronic kidney disease mineral and bone disorder in children. Wesseling K; Bakkaloglu S; Salusky I Pediatr Nephrol; 2008 Feb; 23(2):195-207. PubMed ID: 18046581 [TBL] [Abstract][Full Text] [Related]
64. Brown tumors in dialyzed patients with secondary hyperparathyroidism: report of 16 cases. Hamouda M; Handous I; Ben Dhia N; Ayachi S; Letaief A; Aloui S; Frih A; Skhiri H; Khochtali H; Elmay M Hemodial Int; 2012 Oct; 16(4):497-503. PubMed ID: 22537348 [TBL] [Abstract][Full Text] [Related]
65. [Chronic kidney disease-mineral and bone disorder (CKD-MBD)]. Hamada Y; Fukagawa M Nihon Rinsho; 2006 Sep; 64(9):1703-6. PubMed ID: 16972683 [TBL] [Abstract][Full Text] [Related]
66. Severe renal osteodystrophy in a pediatric patient with end-stage renal disease: Sagliker syndrome? Yavascan O; Kose E; Alparslan C; Sirin Kose S; Bal A; Kanik A; Aksu N J Ren Nutr; 2013 Jul; 23(4):326-30. PubMed ID: 23026501 [TBL] [Abstract][Full Text] [Related]
67. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Moe SM Eur J Clin Invest; 2006 Aug; 36 Suppl 2():51-62. PubMed ID: 16884398 [TBL] [Abstract][Full Text] [Related]
68. Extreme scoliosis from CKD-MBD resulting in respiratory failure and death. Akao S; Nishioka N; Miyasato H; Kinjo M BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30249734 [No Abstract] [Full Text] [Related]
69. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541 [TBL] [Abstract][Full Text] [Related]
70. Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease. Mathew S; Davies M; Lund R; Saab G; Hruska KA Eur J Clin Invest; 2006 Aug; 36 Suppl 2():43-50. PubMed ID: 16884397 [TBL] [Abstract][Full Text] [Related]
71. Adynamic bone disease: from bone to vessels in chronic kidney disease. Bover J; Ureña P; Brandenburg V; Goldsmith D; Ruiz C; DaSilva I; Bosch RJ Semin Nephrol; 2014 Nov; 34(6):626-40. PubMed ID: 25498381 [TBL] [Abstract][Full Text] [Related]
72. Development of a quantitative systems pharmacology model of chronic kidney disease: metabolic bone disorder. Gaweda AE; McBride DE; Lederer ED; Brier ME Am J Physiol Renal Physiol; 2021 Feb; 320(2):F203-F211. PubMed ID: 33308018 [TBL] [Abstract][Full Text] [Related]
73. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients. Dogan E; Erkoc R; Sayarlioglu H; Soyoral Y; Dulger H Ren Fail; 2008; 30(4):407-10. PubMed ID: 18569914 [TBL] [Abstract][Full Text] [Related]
74. Dialysate Calcium Concentration, Mineral Metabolism Disorders, and Cardiovascular Disease: Deciding the Hemodialysis Bath. Langote A; Ahearn M; Zimmerman D Am J Kidney Dis; 2015 Aug; 66(2):348-58. PubMed ID: 25958080 [TBL] [Abstract][Full Text] [Related]
76. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Block GA; Port FK Am J Kidney Dis; 2000 Jun; 35(6):1226-37. PubMed ID: 10845841 [TBL] [Abstract][Full Text] [Related]
77. [New Developments in CKD-MBD. Strategies for the management of predilalysis CKD-MBD]. Ando R Clin Calcium; 2014 Dec; 24(12):1845-51. PubMed ID: 25423931 [TBL] [Abstract][Full Text] [Related]
78. [Update 2017 of the KDIGO guidelines on Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). What are the real changes?]. Pasquali M; Bellasi A; Cianciolo G; Massimetti C; Mereu MC; Morrone L; Panuccio V; G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786179 [TBL] [Abstract][Full Text] [Related]
79. Brown tumors in patients with chronic renal failure and secondary hyperparathyroidism: report of 12 cases. Fatma LB; Barbouch S; Fethi BH; Imen BA; Karima K; Imed H; Fethi el Y; Fatma BM; Rim G; Taieb BA; Maiz HB; Adel K Saudi J Kidney Dis Transpl; 2010 Jul; 21(4):772-7. PubMed ID: 20587894 [TBL] [Abstract][Full Text] [Related]
80. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]